{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:46:51Z","timestamp":1778582811189,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T00:00:00Z","timestamp":1486684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T00:00:00Z","timestamp":1486684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p> To report the long-term safety and efficacy data of a third generation drug eluting stent (DES) with biodegradable polymer in the complex patient population of diabetes mellitus after a follow-up period of 5\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p> After percutaneous coronary intervention patients with diabetes mellitus are under higher risk of death, restenosis and stent thrombosis (ST) compared to non-diabetic patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p> In 126 centers worldwide 3067 patients were enrolled in the NOBORI 2 registry, 888 patients suffered from diabetes mellitus (DM), 213 of them (14%) being insulin dependent (IDDM). Five years follow-up has been completed in this study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At 5\u00a0years, 89.3% of the patients were available for follow-up. The reported target lesion failure (TLF) rates at 5\u00a0years were 12.39% in DM group and 7.34% in non-DM group; (p\u00a0&lt;\u00a00.0001). In the DM group, the TLF rate in patients with IDDM was significantly higher than in the non-IDDM subgroup (17.84 vs. 10.67%; p\u00a0&lt;\u00a00.01). The rate of ST at 5\u00a0years was not different among diabetic versus non-diabetic patients or IDDM versus NIDDM. Only 10 (&lt;0.4%) very late stent thrombotic events beyond 12\u00a0months occurred.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The Nobori DES performed well in patients with DM. As expected patients with DM, particularly those with IDDM, had worse outcomes. However, the very low rate of very late stent thrombosis in IDDM patients might have significant clinical value in the treatment of these patients.<\/jats:p>\n                <jats:p><jats:italic>Clinical trial registration<\/jats:italic> ISRCTN81649913; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.controlled-trials.com\/isrctn\/search.html%3fsrch%3d81649913%26sort%3d3%26dir%3ddesc%26max%3d10\">http:\/\/www.controlled-trials.com\/isrctn\/search.html?srch=81649913&amp;sort=3&amp;dir=desc&amp;max=10<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-017-0500-3","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T20:00:44Z","timestamp":1486670444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5\u00a0years follow-up"],"prefix":"10.1186","volume":"16","clinical-trial-number":[{"clinical-trial-number":"isrctn81649913","registry":"10.18810\/isrctn"}],"author":[{"given":"Marcus","family":"Wiemer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinisa","family":"Stoikovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Samol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zisis","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan M.","family":"Ruiz-Nodar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Birkemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Monsegu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Finet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hildick-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damras","family":"Tresukosol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique Garcia","family":"Novo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques J.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Battista","family":"Danzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of NOBORI 2 investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,10]]},"reference":[{"issue":"2","key":"500_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/01.CIR.103.2.192","volume":"103","author":"JE Sousa","year":"2001","unstructured":"Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103(2):192\u20135.","journal-title":"Circulation"},{"issue":"10","key":"500_CR2","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa067722","volume":"356","author":"B Lagerqvist","year":"2007","unstructured":"Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L, SCAAR\/SWEDEHEART Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356(10):1009\u201319.","journal-title":"N Engl J Med"},{"issue":"2","key":"500_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1161\/CIRCULATIONAHA.104.508937","volume":"112","author":"AV Finn","year":"2005","unstructured":"Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005;112(2):270\u20138.","journal-title":"Circulation"},{"issue":"1","key":"500_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2014.04.022","volume":"64","author":"G Sarno","year":"2014","unstructured":"Sarno G, Lagerqvist B, Nilsson J, Frobert O, Hambraeus K, Varenhorst C, Jensen UJ, Todt T, Gotberg M, James SK. Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR. J Am Coll Cardiol. 2014;64(1):16\u201324.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"500_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1161\/CIRCINTERVENTIONS.108.823443","volume":"2","author":"B Chevalier","year":"2009","unstructured":"Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, Koolen J, Hauptmann KE, Wijns W, Morice MC, et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial\u2014Phase 2. Circ Cardiovasc Interv. 2009;2(3):188\u201395.","journal-title":"Circ Cardiovasc Interv"},{"issue":"6","key":"500_CR6","doi-asserted-by":"publisher","first-page":"E193","DOI":"10.1002\/ccd.25416","volume":"83","author":"A Lupi","year":"2014","unstructured":"Lupi A, Gabrio Secco G, Rognoni A, Lazzero M, Fattori R, Sheiban I, Sante Bongo A, Bolognese L, Agostoni P, Porto I. Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: an update. Catheter Cardiovasc Interv. 2014;83(6):E193\u2013206.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"5","key":"500_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/pat.592","volume":"16","author":"T-Y Liu","year":"2005","unstructured":"Liu T-Y, Lin W-C, Huang L-Y, Chen S-Y, Yang M-C. Surface characteristics and hemocompatibility of PAN\/PVDF blend membranes. Polym Adv Technol. 2005;16(5):413\u20139.","journal-title":"Polym Adv Technol"},{"issue":"15","key":"500_CR8","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1161\/CIRCULATIONAHA.113.002114","volume":"128","author":"EJ Armstrong","year":"2013","unstructured":"Armstrong EJ, Rutledge JC, Rogers JH. Coronary artery revascularization in patients with diabetes mellitus. Circulation. 2013;128(15):1675\u201385.","journal-title":"Circulation"},{"issue":"4","key":"500_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.2337\/dc12-1507","volume":"36","author":"G De Luca","year":"2013","unstructured":"De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, et al. Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation. Diabetes Care. 2013;36(4):1020\u20135.","journal-title":"Diabetes Care"},{"issue":"1","key":"500_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-016-0429-y","volume":"15","author":"Y Harada","year":"2016","unstructured":"Harada Y, Colleran R, Kufner S, Giacoppo D, Rheude T, Michel J, Cassese S, Ibrahim T, Laugwitz KL, Kastrati A, et al. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. Cardiovasc Diabetol. 2016;15(1):124.","journal-title":"Cardiovasc Diabetol"},{"key":"500_CR11","doi-asserted-by":"publisher","first-page":"e5170","DOI":"10.1136\/bmj.e5170","volume":"345","author":"S Bangalore","year":"2012","unstructured":"Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, Williams DO, Slater J, Cutlip DE, Feit F. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ. 2012;345:e5170.","journal-title":"BMJ"},{"key":"500_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2147\/MDER.S67399","volume":"8","author":"M Wiemer","year":"2015","unstructured":"Wiemer M, Danzi GB, West N, Voudris V, Koning R, Hoffmann S, Lombardi M, Mauri J, Babic R, Witherow F. Drug-eluting stents with biodegradable polymer for the treatment of patients with diabetes mellitus: clinical outcome at 2\u00a0years in a large population of patients. Med Devices (Auckl). 2015;8:153\u201360.","journal-title":"Med Devices (Auckl)"},{"issue":"1","key":"500_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4244\/EIJV8I1A17","volume":"8","author":"GB Danzi","year":"2012","unstructured":"Danzi GB, Chevalier B, Urban P, Fath-Ordoubadi F, Carrie D, Wiemer M, Serra A, Wijns W, Kala P, Stabile A, et al. Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study. EuroIntervention. 2012;8(1):109\u201316.","journal-title":"EuroIntervention"},{"issue":"5","key":"500_CR14","first-page":"599","volume":"58","author":"GB Danzi","year":"2010","unstructured":"Danzi GB, Chevalier B, Ostojic M, Hamilos M, Wijns W. Nobori drug eluting stent system: clinical evidence update. Minerva Cardioangiol. 2010;58(5):599\u2013610.","journal-title":"Minerva Cardioangiol"},{"issue":"5","key":"500_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"17","key":"500_CR16","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344\u201351.","journal-title":"Circulation"},{"issue":"1","key":"500_CR17","first-page":"382","volume":"3","author":"Z Fanari","year":"2014","unstructured":"Fanari Z, Weiss SA, Zhang W, Sonnad SS, Weintraub WS. Short, intermediate and long term outcomes of CABG vs. PCI with DES in patients with multivessel coronary artery disease: meta-analysis of six randomized controlled trials. Eur J Cardiovasc Med. 2014;3(1):382\u20139.","journal-title":"Eur J Cardiovasc Med"},{"issue":"5","key":"500_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ccd.23280","volume":"80","author":"K Kadota","year":"2012","unstructured":"Kadota K, Muramatsu T, Iwabuchi M, Saito S, Hayashi Y, Ikari Y, Nanto S, Fujii K, Inoue N, Namiki A, et al. Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. Catheter Cardiovasc Interv. 2012;80(5):789\u201396.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"2","key":"500_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/eurheartj\/ehp424","volume":"31","author":"U Stenestrand","year":"2010","unstructured":"Stenestrand U, James SK, Lindback J, Frobert O, Carlsson J, Schersten F, Nilsson T, Lagerqvist B, SCAAR\/SWEDEHEART Study Group. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2010;31(2):177\u201386.","journal-title":"Eur Heart J"},{"issue":"8","key":"500_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1161\/CIRCULATIONAHA.111.031070","volume":"124","author":"GW Stone","year":"2011","unstructured":"Stone GW, Kedhi E, Kereiakes DJ, Parise H, Fahy M, Serruys PW, Smits PC. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation. 2011;124(8):893\u2013900.","journal-title":"Circulation"},{"issue":"3","key":"500_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.amjcard.2014.10.038","volume":"115","author":"KK Olesen","year":"2015","unstructured":"Olesen KK, Tilsted HH, Jensen LO, Kaltoft A, Krusell LR, Ravkilde J, Christiansen EH, Madsen M, Thayssen P, Sorensen HT, et al. Long-term outcome of sirolimus-eluting and zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a Danish organization for randomized trials on clinical outcome III substudy). Am J Cardiol. 2015;115(3):298\u2013302.","journal-title":"Am J Cardiol"},{"issue":"5","key":"500_CR22","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ahj.2012.02.014","volume":"163","author":"M Billinger","year":"2012","unstructured":"Billinger M, Raber L, Hitz S, Stefanini GG, Pilgrim T, Stettler C, Zanchin T, Pulver C, Pfaffli N, Eberli F, et al. Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. Am Heart J. 2012;163(5):876\u201386.","journal-title":"Am Heart J"},{"issue":"3","key":"500_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jcin.2010.12.004","volume":"4","author":"Y Onuma","year":"2011","unstructured":"Onuma Y, Wykrzykowska JJ, Garg S, Vranckx P, Serruys PW, Arts I, Investigators II. 5-Year follow-up of coronary revascularization in diabetic patients with multivessel coronary artery disease: insights from ARTS (arterial revascularization therapy study)-II and ARTS-I trials. JACC Cardiovasc Interv. 2011;4(3):317\u201323.","journal-title":"JACC Cardiovasc Interv"},{"issue":"7","key":"500_CR24","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/ccd.25875","volume":"86","author":"M Maeng","year":"2015","unstructured":"Maeng M, Baranauskas A, Christiansen EH, Kaltoft A, Holm NR, Krusell LR, Ravkilde J, Tilsted HH, Thayssen P, Jensen LO. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial). Catheter Cardiovasc Interv. 2015;86(7):1161\u20137.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"500_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijcard.2013.10.006","volume":"170","author":"C Simsek","year":"2013","unstructured":"Simsek C, Raber L, Magro M, Boersma E, Onuma Y, Stefanini GG, Zanchin T, Kalesan B, Wenaweser P, Juni P, et al. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study. Int J Cardiol. 2013;170(1):36\u201342.","journal-title":"Int J Cardiol"},{"issue":"3","key":"500_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ccd.25131","volume":"83","author":"T Stiermaier","year":"2014","unstructured":"Stiermaier T, Heinz A, Schloma D, Kleinertz K, Danschel W, Erbs S, Linke A, Boudriot E, Lauer B, Schuler G, et al. Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial). Catheter Cardiovasc Interv. 2014;83(3):418\u201324.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"500_CR27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ahj.2011.12.010","volume":"163","author":"JM Sinning","year":"2012","unstructured":"Sinning JM, Baumgart D, Werner N, Klauss V, Baer FM, Hartmann F, Drexler H, Motz W, Klues H, Voelker W, et al. Five-year results of the multicenter randomized controlled open-label study of the CYPHER sirolimus-eluting stent in the treatment of diabetic patients with de novo native coronary artery lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. Am Heart J. 2012;163(3):446\u201353.","journal-title":"Am Heart J"},{"issue":"3","key":"500_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12928-012-0115-2","volume":"27","author":"T Sato","year":"2012","unstructured":"Sato T, Ono T, Morimoto Y, Kawai H, Fuke S, Ikeda T, Saito H. Five-year clinical outcomes after implantation of sirolimus-eluting stents in patients with and without diabetes mellitus. Cardiovasc Interv Ther. 2012;27(3):189\u201395.","journal-title":"Cardiovasc Interv Ther"},{"issue":"2","key":"500_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1161\/CIRCINTERVENTIONS.111.964650","volume":"5","author":"K Park","year":"2012","unstructured":"Park K, Park KW, Rha SW, Bae JH, Hur SH, Park JS, Yoon JH, Jang Y, Jeong MH, Kim HS. Comparison of 5-year clinical outcomes between sirolimus-versus paclitaxel-eluting stent: Korean multicenter network analysis of 9000-patient cohort. Circ Cardiovasc Interv. 2012;5(2):174\u201384.","journal-title":"Circ Cardiovasc Interv"},{"issue":"7","key":"500_CR30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/ccd.25045","volume":"82","author":"M Vardi","year":"2013","unstructured":"Vardi M, Burke DA, Bangalore S, Pencina MJ, Mauri L, Kandzari DE, Leon MB, Cutlip DE. Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials. Catheter Cardiovasc Interv. 2013;82(7):1031\u20138.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"9","key":"500_CR31","first-page":"417","volume":"26","author":"K Yahagi","year":"2014","unstructured":"Yahagi K, Joner M, Virmani R. Insights into very late stent thrombosis from the wisdom of pathology. J Invasive Cardiol. 2014;26(9):417\u20139.","journal-title":"J Invasive Cardiol"},{"issue":"5","key":"500_CR32","first-page":"567","volume":"57","author":"RA Byrne","year":"2009","unstructured":"Byrne RA, Joner M, Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol. 2009;57(5):567\u201384.","journal-title":"Minerva Cardioangiol"},{"issue":"4","key":"500_CR33","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2010.05.066","volume":"57","author":"G Nakazawa","year":"2011","unstructured":"Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol. 2011;57(4):390\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"500_CR34","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","volume":"33","author":"GG Stefanini","year":"2012","unstructured":"Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Juni P, Schomig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4\u00a0years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33(10):1214\u201322.","journal-title":"Eur Heart J"},{"issue":"6","key":"500_CR35","doi-asserted-by":"publisher","first-page":"5162","DOI":"10.1016\/j.ijcard.2013.07.263","volume":"168","author":"A de Waha","year":"2013","unstructured":"de Waha A, Stefanini GG, King LA, Byrne RA, Serruys PW, Kufner S, Meier B, Juni P, Kastrati A, Windecker S. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. Int J Cardiol. 2013;168(6):5162\u20136.","journal-title":"Int J Cardiol"},{"issue":"8","key":"500_CR36","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.cjca.2015.02.036","volume":"31","author":"A Konishi","year":"2015","unstructured":"Konishi A, Shinke T, Otake H, Takaya T, Osue T, Kinutani H, Kuroda M, Takahashi H, Terashita D, Shite J, et al. Serial optical coherence tomography evaluation at 6, 12, and 24 months after Biolimus A9-eluting biodegradable polymer-coated stent implantation. Can J Cardiol. 2015;31(8):980\u20138.","journal-title":"Can J Cardiol"},{"issue":"1","key":"500_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2014.08.031","volume":"237","author":"S Kuramitsu","year":"2014","unstructured":"Kuramitsu S, Sonoda S, Yokoi H, Iwabuchi M, Nishizaki Y, Shinozaki T, Domei T, Hyodo M, Inoue K, Shirai S, et al. Long-term coronary arterial response to biodegradable polymer biolimus-eluting stents in comparison with durable polymer sirolimus-eluting stents and bare-metal stents: five-year follow-up optical coherence tomography study. Atherosclerosis. 2014;237(1):23\u20139.","journal-title":"Atherosclerosis"}],"updated-by":[{"DOI":"10.1186\/s12933-017-0541-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000}}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-017-0500-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-017-0500-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-017-0500-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T11:59:19Z","timestamp":1628596759000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-017-0500-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,10]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["500"],"URL":"https:\/\/doi.org\/10.1186\/s12933-017-0500-3","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12933-017-0541-7","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,10]]},"assertion":[{"value":"9 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"23"}}